Related Experiment Video
Updated: Mar 3, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.3K
Danshen injection prevents heart failure by attenuating post-infarct remodeling
Lingyan Wang1, Jiahui Yu1, Patrick Asare Fordjour1
1State Key Laboratory of Modern Chinese Medicine, Tianjin University of traditional Chinese Medicine, Tianjin, PR China.
Journal of Ethnopharmacology
|May 4, 2017
Summary
Danshen Injection (DSI) effectively treats heart injury by improving cardiac function and reducing fibrosis. It also exhibits anti-inflammatory and cell-protective effects, offering a promising therapeutic option for cardiovascular diseases.
Area of Science:
- Cardiovascular Research
- Traditional Chinese Medicine Pharmacology
- Integrative Medicine
Background:
- Danshen Injection (DSI), derived from Salvia miltiorrhiza Bunge, is a traditional Chinese medicine used to improve blood circulation and reduce stasis.
- Traditionally, DSI is recognized for its cooling properties, aiding in reducing swelling and inflammation.
Purpose of the Study:
- To investigate the efficacy and underlying mechanisms of Danshen Injection (DSI) in treating myocardial infarction (MI) induced by left anterior descending (LAD) artery ligation in a rat model.
- To evaluate DSI's impact on cardiac function, myocardial fibrosis, and key molecular markers associated with cardiac remodeling and inflammation.
Main Methods:
- Adult male Sprague-Dawley rats underwent LAD surgery and were randomized into MI, DSI, and Valsartan groups.
- Cardiac function was assessed using echocardiography and Pressure-Volume loop measurements.
- Myocardial fibrosis was evaluated via Masson and Sirus red staining, while protein and gene expression of MMP-2, MMP-9, iNOS, MPO, Bcl-2, and Bax were analyzed using Western blotting and RT-PCR.
Main Results:
- DSI administration significantly improved cardiac function, hemodynamic parameters, and normalized ventricular mass in LAD-induced MI rats.
- DSI treatment regulated myocardial collagen deposition, modulated MMP-2 expression, and decreased the gene expression of inflammatory markers (iNOS, MPO, MMP-9).
- A significant increase in the Bcl-2/Bax ratio was observed in the DSI group, suggesting a protective effect against cell death.
Conclusions:
- Danshen Injection (DSI) effectively prevents myocardial fibrosis, cardiac hypertrophy, and functional deterioration in a rat model of heart injury.
- DSI exhibits anti-inflammatory properties by reducing iNOS and MPO expression and may inhibit cell death by increasing the Bcl-2/Bax ratio.
- Further research into DSI's anti-hypertrophic mechanisms and the role of MMP-2 in myocardial hypertrophy is warranted.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
429
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
429
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:29Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K